Published in Immunity on January 09, 2014
The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides. Immunity (2014) 1.97
A Novel Glycolipid Antigen for NKT Cells That Preferentially Induces IFN-γ Production. J Immunol (2015) 0.96
The regulatory role of invariant NKT cells in tumor immunity. Cancer Immunol Res (2015) 0.96
Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models. Front Immunol (2015) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents. Clin Transl Immunology (2016) 0.88
Ontogeny of myeloid cells. Front Immunol (2014) 0.87
Complementary diversification of dendritic cells and innate lymphoid cells. Curr Opin Immunol (2014) 0.84
Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLoS One (2014) 0.82
The Alpha and Omega of Galactosylceramides in T Cell Immune Function. J Biol Chem (2015) 0.82
Fate mapping of dendritic cells. Front Immunol (2015) 0.81
Selective Conditions Are Required for the Induction of Invariant NKT Cell Hyporesponsiveness by Antigenic Stimulation. J Immunol (2015) 0.79
Role of Group 1 CD1-Restricted T Cells in Infectious Disease. Front Immunol (2015) 0.79
iNKT Cell Emigration out of the Lung Vasculature Requires Neutrophils and Monocyte-Derived Dendritic Cells in Inflammation. Cell Rep (2016) 0.78
α-Galactosylceramide-activated murine NK1.1(+) invariant-NKT cells in the myometrium induce miscarriages in mice. Eur J Immunol (2016) 0.78
iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. J Immunother Cancer (2014) 0.78
Glycolipid activators of invariant NKT cells as vaccine adjuvants. Immunogenetics (2016) 0.76
Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset. Immunogenetics (2016) 0.76
Activation strategies for invariant natural killer T cells. Immunogenetics (2016) 0.76
Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential. Front Immunol (2017) 0.75
Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes. Chem Phys Lipids (2015) 0.75
A Subset of CD8αβ+ Invariant NKT Cells in a Humanized Mouse Model. J Immunol (2015) 0.75
Isolation and In vivo Transfer of Antigen Presenting Cells. Bio Protoc (2014) 0.75
CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control. Oncoimmunology (2016) 0.75
Professional differences in antigen presentation to iNKT cells. Immunity (2014) 0.75
Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza. MBio (2016) 0.75
Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood (2017) 0.75
Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy. Front Immunol (2017) 0.75
NIH Image to ImageJ: 25 years of image analysis. Nat Methods (2012) 84.41
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science (2009) 10.47
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol (2003) 6.07
Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol (1999) 5.86
A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature (2001) 5.08
Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nat Immunol (2011) 3.48
Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol (2013) 2.89
Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A (2005) 2.83
Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med (2003) 2.64
Apolipoprotein-mediated pathways of lipid antigen presentation. Nature (2005) 2.61
Lipid length controls antigen entry into endosomal and nonendosomal pathways for CD1b presentation. Nat Immunol (2002) 2.54
Recognition of CD1d-restricted antigens by natural killer T cells. Nat Rev Immunol (2012) 2.32
An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol (2010) 2.03
Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity (2009) 2.00
Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol (2009) 1.81
CD169(+) macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nat Immunol (2010) 1.76
Mouse CD1 is mainly expressed on hemopoietic-derived cells. J Immunol (1997) 1.73
Distinct roles of dendritic cells and B cells in Va14Ja18 natural T cell activation in vivo. J Immunol (2005) 1.67
Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol (2009) 1.44
Production and characterization of monoclonal antibodies against complexes of the NKT cell ligand alpha-galactosylceramide bound to mouse CD1d. J Immunol Methods (2007) 1.37
Improved outcomes in NOD mice treated with a novel Th2 cytokine-biasing NKT cell activator. J Immunol (2007) 1.36
The location of splenic NKT cells favours their rapid activation by blood-borne antigen. EMBO J (2012) 1.18
Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol (2009) 1.18
Distinct APCs explain the cytokine bias of α-galactosylceramide variants in vivo. J Immunol (2012) 1.15
Scavenger receptors target glycolipids for natural killer T cell activation. J Clin Invest (2012) 1.13
Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cells. J Immunol (2008) 1.12
Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy (2010) 1.06
Glycolipids that elicit IFN-γ-biased responses from natural killer T cells. Chem Biol (2011) 1.05
New BODIPY lipid probes for fluorescence studies of membranes. J Lipid Res (2007) 0.99
Structural basis for the recognition of C20:2-αGalCer by the invariant natural killer T cell receptor-like antibody L363. J Biol Chem (2011) 0.97
Α-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents. PLoS One (2010) 0.93
IL-18 skews the invariant NKT-cell population via autoreactive activation in atopic eczema. Eur J Immunol (2009) 0.92
Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Proc Natl Acad Sci U S A (2011) 0.91
The mechanism of splenic invariant NKT cell activation dictates localization in vivo. J Immunol (2013) 0.89
A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids. J Am Chem Soc (2011) 0.88
Regulated recruitment of MHC class II and costimulatory molecules to lipid rafts in dendritic cells. J Immunol (2004) 0.88
Synthesis and biological activity of alpha-galactosyl ceramide KRN7000 and galactosyl (alpha1-->2) galactosyl ceramide. Bioorg Med Chem Lett (2009) 0.98
Synthesis and biological activity of alpha-L-fucosyl ceramides, analogues of the potent agonist, alpha-D-galactosyl ceramide KRN7000. Bioorg Med Chem Lett (2010) 0.80
CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis. Adv Exp Med Biol (2013) 0.80
Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues. Carbohydr Res (2012) 0.79
New CD1d agonists: synthesis and biological activity of 6″-triazole-substituted α-galactosyl ceramides. Bioorg Med Chem Lett (2012) 0.78
Synthesis of truncated analogues of the iNKT cell agonist, α-galactosyl ceramide (KRN7000), and their biological evaluation. Bioorg Med Chem (2010) 0.77
A glycan shield for bacterial sphingolipids. Chem Biol (2008) 0.77
"Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes". Chem Phys Lipids (2015) 0.76
Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes. Chem Phys Lipids (2015) 0.75